Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Curcumin for the Prevention of Colon Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Michigan Cancer Center Identifier:
First received: December 7, 2001
Last updated: December 19, 2012
Last verified: December 2012

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Curcumin may be effective in preventing the development of colon cancer.

PURPOSE: Phase I trial to determine the dose amount of curcumin that can be tolerated to help in preventing colon cancer in healthy men and women.

Condition Intervention Phase
Colorectal Cancer
Dietary Supplement: curcumin
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Prevention
Official Title: Phase I Pharmacokinetic Trial of Curcuminoids Administered in a Capsule Formulation

Resource links provided by NLM:

Further study details as provided by University of Michigan Cancer Center:

Study Start Date: December 2001
Study Completion Date: September 2007
Primary Completion Date: February 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated dose (MTD) of curcumin as a chemopreventive agent of colon cancer in healthy subjects.
  • Determine if tolerable doses of this agent in uniformly milled formulation capsules are bioavailable in these subjects.
  • Determine the pharmacokinetics of this agent and two metabolites at the MTD and next lower escalated dose in these subjects.

OUTLINE: This is a dose escalation study followed by a pharmacokinetic study.

Patients receive a single oral dose of curcumin followed by a standard fatty meal.

Cohorts of 3-6 patients receive escalating doses of curcumin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicities. Once the MTD is determined, additional patients are accrued to receive curcumin in the pharmacokinetic phase of the study.

Patients are followed at 24, 36, 48, and 72 hours.

PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the dose escalation phase and then 12 additional patients will be accrued for the pharmacokinetic phase of this study within 3 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Healthy men and women age 18 and over



  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • WBC greater than 4,000/mm3
  • Hemoglobin greater than 12 g/dL
  • Platelet count greater than 120,000/mm3


  • ALT/AST less than 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase less than 1.5 times ULN
  • Bilirubin less than 1.5 mg/dL


  • Creatinine less than 1.7 mg/dL


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior cancer except surgically resected basal cell or squamous cell skin cancer
  • No history of peptic ulcer disease, gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors
  • No history of unreliability or noncompliance (missing pretreatment appointment more than twice)


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • At least 14 days since prior steroids


  • Not specified


  • Not specified


  • At least 14 days since prior curcumin (turmeric) rich foods
  • At least 14 days since prior nonsteroidal antiinflammatory drugs (NSAIDs)
  • No chronic medications (i.e., daily for more than 28 days) except for oral contraceptives
  • No concurrent coumadin or other anticoagulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00027495

United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109-0930
Sponsors and Collaborators
University of Michigan Cancer Center
National Cancer Institute (NCI)
Study Chair: Dean E. Brenner, MD University of Michigan Cancer Center
  More Information

Responsible Party: University of Michigan Cancer Center Identifier: NCT00027495     History of Changes
Other Study ID Numbers: CDR0000067916
P30CA046592 ( US NIH Grant/Contract Award Number )
CCUM-9941 ( Other Identifier: University of Michigan Cancer Center PRC )
Study First Received: December 7, 2001
Last Updated: December 19, 2012

Keywords provided by University of Michigan Cancer Center:
colon cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 26, 2017